Middle East And Africa Liver Fibrosis Treatment Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
USD
935.44 Million
USD
2,354.75 Million
2024
2032
 Período de previsão |
2025 –2032 |
 Tamanho do mercado (ano base ) | USD 935.44 Million |
 Tamanho do mercado ( Ano de previsão) | USD 2,354.75 Million |
 CAGR |
% |
| Principais participantes do mercado |
Mercado de tratamento da fibrose hepática no Médio Oriente e África, por tipo de tratamento (medicação e cirurgia/terapia), estádios (F2, F1, F3 e F4), indicação (esteato-hepatite não alcoólica (EHNA), fibrose induzida por hepatite B e C, doença hepática alcoólica (ALD), doenças hepáticas autoimunes, doenças genéticas e outras), género (masculino e feminino), utilizador final (hospitais, clínicas especializadas, clínicas, centros de ambulatório e de investigação e outros), canal de distribuição ( e vendas a retalho) - tendências do setor e previsão até 2032
Tamanho do mercado de tratamento da fibrose hepática no Médio Oriente e África
- O mercado de tratamento da fibrose hepática no Médio Oriente e em África foi avaliado em 935,44 milhões de dólares em 2024 e deverá atingir os 2.354,75 milhões de dólares até 2032
- Durante o período previsto de 2025 a 2032, o mercado deverá crescer a um CAGR de 12,3%, impulsionado principalmente pela crescente consciencialização dos consumidores sobre as soluções naturais de saúde
- Este crescimento é impulsionado por fatores como o aumento da prevalência de doenças hepáticas. Além disso, a acessibilidade impulsiona o aumento do consumo de álcool.
Análise do Mercado de Tratamento da Fibrose Hepática no Médio Oriente e África
- O número crescente de doenças hepáticas cria uma maior população de doentes que necessitam de opções terapêuticas eficazes, especialmente para condições como a hepatite B e C. Fatores contribuintes, como o aumento do consumo de álcool, hábitos alimentares pouco saudáveis e um aumento das taxas de obesidade, levaram ao diagnóstico de mais pessoas com estas doenças hepáticas.
- À medida que os danos hepáticos avançam, o risco de desenvolver fibrose hepática aumenta, colocando uma carga significativa nos sistemas de saúde para oferecer opções de tratamento eficazes. Esta crescente procura impulsiona o desenvolvimento e a disponibilidade de terapias direcionadas, alimentando o crescimento do mercado à medida que os prestadores de cuidados de saúde procuram soluções inovadoras para a gestão desta condição.
- Além disso, a crescente consciencialização entre os profissionais de saúde e o público em geral levou a que mais indivíduos fossem examinados e diagnosticados em fases iniciais da doença hepática. Os avanços nas técnicas de diagnóstico, incluindo exames de imagem e de sangue não invasivos, facilitaram a identificação da fibrose hepática mais cedo na progressão da doença. Esta detecção precoce permite intervenções oportunas, estimulando a procura de tratamentos inovadores que revertam ou controlem eficazmente a fibrose hepática.
- Por exemplo, em agosto de 2023, de acordo com um artigo publicado pelo NCBI, a doença hepática é responsável por dois milhões de mortes anualmente e é responsável por 4% de todas as mortes (1 em cada 25 mortes no mundo); aproximadamente dois terços de todas as mortes relacionadas com o fígado ocorrem em homens. Esta estatística alarmante sublinha a necessidade urgente de opções de tratamento eficazes e realça o significativo fardo para a saúde pública imposto pelas doenças hepáticas, motivando ainda mais os sistemas de saúde e as empresas farmacêuticas a priorizar o desenvolvimento de terapias inovadoras que visem especificamente a fibrose hepática e as suas causas subjacentes.
- Consequentemente, as empresas farmacêuticas e os investigadores médicos são obrigados a investir no desenvolvimento de novas opções terapêuticas, impulsionando assim o mercado, à medida que os intervenientes procuram combater a crescente incidência de doenças hepáticas e as suas complicações associadas.
Âmbito do relatório e segmentação do mercado de tratamento da fibrose hepática no Médio Oriente e África
|
Atributos |
Principais insights do mercado global de tratamento da fibrose hepática |
|
Segmentos abrangidos |
|
|
Países abrangidos |
|
|
Principais participantes do mercado |
|
|
Oportunidades de mercado |
|
|
Conjuntos de informações de dados de valor acrescentado |
Para além dos insights sobre os cenários de mercado, tais como o valor de mercado, a taxa de crescimento, a segmentação, a cobertura geográfica e os principais participantes, os relatórios de mercado selecionados pela Data Bridge Market Research incluem também a análise de importação e exportação, a visão geral da capacidade de produção, a análise do consumo de produção, a análise da tendência dos preços, o cenário das alterações climáticas, a análise da cadeia de abastecimento, a análise da cadeia de valor, a visão geral da matéria-prima/consumíveis, os critérios de seleção de fornecedores, a análise PESTLE, a análise de Porter e a estrutura regulamentar. |
Tendências do mercado de tratamento da fibrose hepática no Médio Oriente e em África
“Aumento da prevalência de doenças hepáticas”
- A crescente prevalência de doenças hepáticas está a emergir como uma preocupação significativa para a saúde no Médio Oriente e em África, contribuindo substancialmente para os problemas de saúde em todo o mundo.
- Fatores como o consumo excessivo de álcool, o aumento das taxas de obesidade, as infeções por hepatite viral e estilos de vida pouco saudáveis estão a levar a um aumento de condições como a doença hepática gordurosa, a cirrose e o cancro do fígado.
- A crescente incidência de doença hepática gordurosa não alcoólica (DHGNA), particularmente associada à diabetes e à síndrome metabólica, é também alarmante. Como resultado, há uma procura crescente por diagnóstico precoce, opções de tratamento eficazes e iniciativas de saúde pública. Espera-se que esta tendência impulsione a inovação e o crescimento no mercado de tratamento de doenças hepáticas
Dinâmica do mercado de tratamento da fibrose hepática no Médio Oriente e em África
Motoristas
“Aumento do consumo de álcool”
- O aumento do consumo de álcool contribui significativamente para o mercado de tratamento da fibrose hepática no Médio Oriente e em África devido à sua correlação direta com a incidência de doenças hepáticas, particularmente a Doença Hepática Alcoólica (DAF).
- À medida que mais indivíduos consomem álcool regularmente e em maiores quantidades, o risco de desenvolver complicações relacionadas com o fígado, incluindo fibrose hepática e cirrose, aumenta significativamente
- O alcoolismo crónico leva à inflamação, à acumulação de gordura e, em última análise, à fibrose, à medida que o fígado sofre danos e reparações repetidas.
- Esta crescente prevalência de doenças hepáticas relacionadas com o álcool cria uma procura urgente por tratamentos e estratégias de gestão eficazes para ajudar a mitigar os danos hepáticos e melhorar os resultados dos doentes
Por exemplo,
- Em outubro de 2024, de acordo com um artigo publicado pelo International Journal of Mental Health Systems, a prevalência do consumo de álcool foi de 54,5% e 47,7% no início e no seguimento, respetivamente. Além disso, 12% dos homens referiram ter começado a beber recentemente. Esta prevalência do consumo de álcool leva a um aumento da incidência de fibrose hepática no Médio Oriente e em África, impactando potencialmente o crescimento do mercado
- Em Junho de 2024, de acordo com o STAT, as mortes relacionadas com o álcool estão a aumentar, e os especialistas estão particularmente preocupados com o aumento entre os jovens e as mulheres. Os EUA registaram um aumento de 25,5% nas mortes relacionadas com o álcool entre 2019 e 2020 — representando 3% de todas as mortes. Além disso, os maiores aumentos nas mortes relacionadas com o álcool ocorreram entre as pessoas dos 25 aos 34 e dos 35 aos 44 anos, onde as mortes em ambos os grupos aumentaram mais de 37%.
- Além disso, a crescente aceitação social e a normalização do consumo de álcool, particularmente nos grupos demográficos mais jovens, agravam ainda mais o problema, levando a um maior número de indivíduos em risco de alterações fibróticas no fígado.
- Esta tendência promove o crescimento do mercado de tratamento da fibrose hepática e enfatiza a importância das iniciativas de saúde pública que visam a redução do consumo de álcool e a prevenção de doenças hepáticas.
Oportunidades
“Tecnologias emergentes e tratamentos avançados no tratamento da fibrose hepática”
-
Tecnologias emergentes como a terapia genética, as terapias moleculares dirigidas e os agentes biológicos estão a transformar o panorama do tratamento
-
As inovações recentes centram-se em medicamentos que visam especificamente as vias de progressão da fibrose, como os agonistas do FXR, os inibidores do TGF-β e os agentes anti-inflamatórios. Além disso, ferramentas de diagnóstico não invasivas como a elastografia estão a melhorar a deteção precoce
-
Estes avanços oferecem tratamentos mais eficazes e personalizados para condições como a NASH (esteato-hepatite não alcoólica) e a cirrose, levando a melhores resultados para os doentes.
-
Em fevereiro de 2024, um artigo publicado na Springer Nature, O artigo analisa as abordagens emergentes para diagnosticar e inibir a fibrogénese hepática. Os avanços incluem biomarcadores não invasivos, tecnologias de imagem e terapias celulares, como as células estaminais mesenquimais. Os medicamentos antifibróticos promissores, incluindo a pirfenidona e o ácido obeticólico, juntamente com as inovações na engenharia de tecidos, nanotecnologia e modelos microfluídicos, mostram potencial para tratamentos personalizados e de precisão.
-
Um artigo de setembro de 2021 do NCBI destacou que as tecnologias emergentes no tratamento da fibrose hepática se concentram em terapias avançadas que visam vias moleculares, como a ativação das células estreladas hepáticas. Inovações como a terapia genética, produtos biológicos, inibidores de pequenas moléculas e diagnósticos não invasivos melhoram a deteção e o tratamento precoces. As terapias com células estaminais e a engenharia de tecidos também prometem reverter a fibrose e melhorar a recuperação
-
Com a evolução contínua das estratégias de tratamento e das tecnologias de diagnóstico, as terapêuticas para a fibrose hepática estão a avançar rapidamente
-
Estas inovações oferecem esperança para uma melhor gestão das doenças hepáticas, garantindo que os doentes têm acesso a tratamentos mais eficazes e personalizados, com menos efeitos secundários, melhorando, em última análise, os resultados de saúde no Médio Oriente e em África.
Restrições/Desafio
“ Consciência limitada sobre as doenças hepáticas”
- A limitada sensibilização sobre as doenças do fígado dificulta o diagnóstico precoce e a intervenção adequada. Muitas pessoas desconhecem os factores de risco e os sintomas associados às doenças hepáticas, atribuindo frequentemente sinais vagos de doença a outros problemas menos graves.
- Esta falta de conhecimento adia as consultas médicas até que a doença evolua para fases avançadas, como a fibrose hepática ou a cirrose, onde as opções de tratamento se tornam mais complexas e menos eficazes.
- Consequentemente, os diagnósticos tardios reduzem o potencial de resultados bem-sucedidos do tratamento e restringem o crescimento global do mercado, ao limitar a população de doentes que procura cuidados atempados.
Por exemplo,
- Em abril de 2024, Lupin afirmou que os doentes não têm conhecimento da sua condição até que a doença atinja um estágio crítico, desencadeando uma necessidade urgente de reavaliar a abordagem de sensibilização, deteção e tratamento da saúde do fígado. No entanto, um obstáculo significativo na gestão da saúde hepática reside na compreensão limitada das doenças hepáticas e dos factores de risco associados
- Em julho de 2021, de acordo com um estudo que incluiu 11.700 adultos (maiores de 18 anos) de cinco Inquéritos Nacionais de Exame de Saúde e Nutrição, quase 96% dos adultos com DHGNA nos EUA não sabiam que tinham doença hepática, especialmente entre os adultos jovens. Por conseguinte, aumentar a sensibilização e a educação sobre a saúde hepática é crucial para melhorar os resultados dos doentes e promover uma abordagem mais proativa à gestão da fibrose hepática e à expansão do mercado de tratamento.
- Em janeiro de 2021, a Springer Nature informou que, entre os 825 doentes incluídos na análise da investigação realizada no artigo científico "Falta de sensibilização para os danos hepáticos em doentes com diabetes tipo 2", 8,1% (IC 95% 5,1%-12,7%) dos doentes com esteatose sabiam que tinham uma doença hepática. Além disso, numa amostra nacionalmente representativa de adultos norte-americanos com DM2, a prevalência de fibrose hepática avançada é elevada. Menos de 20% das pessoas com fibrose avançada sabem que têm alguma doença hepática
- A sensibilização limitada prejudica os resultados potenciais do tratamento para os doentes e sufoca o crescimento do mercado ao reduzir o número de indivíduos que interagem com os serviços de saúde desde o início
- Assim, aumentar a sensibilização e a educação sobre a saúde hepática é crucial para melhorar o diagnóstico precoce, aumentar a eficácia do tratamento e, em última análise, promover um mercado mais robusto para as terapias para a fibrose hepática.
Âmbito do mercado de tratamento da fibrose hepática no Médio Oriente e África
O mercado é segmentado com base no tipo de produto, tratamento, base de origem, aplicação, via de administração, modo de compra, faixa etária, género, utilizador final e canal de distribuição.
|
Segmentação |
Sub-segmentação |
|
Por tipo de tratamento |
|
|
Por etapas |
|
|
Por Indicação |
|
|
Por utilizador final |
|
|
Por canal de distribuição |
|
“A Arábia Saudita é o país dominante no mercado de tratamento da fibrose hepática”
- A Arábia Saudita lidera o mercado de tratamento da fibrose hepática no Médio Oriente e em África, impulsionada por uma elevada prevalência de doenças hepáticas, particularmente a doença hepática gordurosa não alcoólica (DHGNA) e a hepatite C, juntamente com um forte foco na modernização dos cuidados de saúde no âmbito da iniciativa Vision 2030
- O país possui uma infraestrutura de cuidados de saúde em rápida evolução, com investimentos governamentais significativos em clínicas especializadas em doenças hepáticas, tecnologias de diagnóstico avançadas e modalidades de tratamento não invasivas.
- Os programas de rastreio generalizados, juntamente com uma maior sensibilização e educação dos doentes, aumentaram as taxas de deteção precoce, aumentando ainda mais a procura de terapêuticas eficazes para a fibrose hepática.
- A estratégia nacional de saúde da Arábia Saudita enfatiza o combate às doenças hepáticas crónicas através de cuidados preventivos, investigação e melhores protocolos de gestão de doenças
“A Arábia Saudita deverá registar a maior taxa de crescimento”
- Prevê-se que a Arábia Saudita seja o país com o crescimento mais rápido no mercado devido à adoção de biomarcadores de ponta, à maior disponibilidade de terapias antifibróticas inovadoras e ao crescente envolvimento das empresas farmacêuticas do Médio Oriente e de África.
- Estes factores posicionam colectivamente a Arábia Saudita como o maior e mais rápido mercado de crescimento para o tratamento da fibrose hepática no Médio Oriente e em África, servindo de modelo para a transformação regional da saúde.
Participação no mercado de tratamento da fibrose hepática no Médio Oriente e África
O cenário competitivo do mercado fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença no Médio Oriente e África, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produtos, amplitude e abrangência do produto, domínio da aplicação. Os pontos de dados fornecidos acima estão apenas relacionados com o foco das empresas em relação ao mercado.
Os principais líderes de mercado que operam no mercado são:
- F. Hoffmann-La Roche Ltd (Suíça)
- Abbott (EUA)
- La Renon Healthcare Pvt. Lda. (Índia)
- GENFIT SA (França)
- Madrigal Pharmaceuticals (EUA)
- Aligos Therapeutics (EUA)
- Pfizer, Lda. (EUA)
- Enanta Pharmaceuticals, Inc.
- Bristol-Myers Squibb Company (EUA)
- Vertex Pharmaceuticals Incorporated (EUA)
- Takeda Pharmaceutical Company Limited (Japão)
- Hepion Pharmaceuticals (EUA)
- Echosens (França)
- Galectin Therapeutics, Inc. (EUA)
- Conatus Pharmaceuticals (EUA)
- Tvardi Therapeutics (EUA)
- Viking Therapeutics (EUA)
- Calliditas Therapeutics AB (Suécia)
- Novomedix (EUA)
- Galecto Biotech (Dinamarca)
- Pilant Therapeutics, Inc. (EUA)
- Sagimet Biosciences (EUA)
- Gyre Therapeutics, Inc. (EUA)
- Akero Therapeutics, Inc. (EUA)
- CureVac SE (Alemanha)
- Novo Nordisk A/S (Dinamarca)
- Ipsen Pharma (França)
- AdAlta Limited (Austrália)
- Alentis Therapeutics AG (Suíça)
- Gilead Sciences, Inc. (EUA)
- AbbVie, Lda. (EUA)
- Merck & Co., Inc. (EUA)
- Novartis AG (Suíça)
- Intercept Pharmaceuticals, Inc. (EUA)
Últimos desenvolvimentos no mercado de tratamento da fibrose hepática no Médio Oriente e em África
- Em junho de 2024, a Gilead Sciences apresentou a nova investigação no Congresso da Associação para o Estudo do Fígado (EASL) de 2024, em Milão, com foco em doenças hepáticas como a colangite biliar primária (CBP), hepatite B (VHB), vírus da hepatite delta (VHD) e outras. As principais apresentações incluirão dados a longo prazo do estudo ASSURE sobre seladelpar para PBC, resultados sobre tenofovir para prevenção do cancro do fígado no VHB e conclusões dos estudos MYR204 e MYR301 sobre Hepcludex para HDV. Esta investigação destaca o compromisso da Gilead em avançar nas opções de tratamento para as doenças do fígado
- Em outubro de 2024, a Intercept Pharmaceuticals, Inc discutiu os seus esforços contínuos para explorar as diferenças e disparidades raciais no tratamento da colangite biliar primária (CBP). A empresa está a abordar como diferentes populações podem enfrentar diferentes desafios no diagnóstico, tratamento e gestão da PBC. Ao explorar estas disparidades, o Intercept visa melhorar o acesso aos cuidados e aos resultados do tratamento para todos os doentes, reduzindo potencialmente as barreiras ao tratamento eficaz das doenças hepáticas, incluindo a fibrose.
- Em novembro de 2022, a Food and Drug Administration (FDA) dos EUA aprovou o Vemlidy (tenofovir alafenamida) para o tratamento da infeção crónica pelo vírus da hepatite B (HBV) em doentes pediátricos com 12 anos ou mais com doença hepática compensada. Esta aprovação alarga a utilização do Vemlidy, que foi inicialmente aprovado em 2016 para adultos com VHB crónico. A aprovação baseia-se num ensaio clínico de Fase 2 que demonstra a eficácia e segurança do Vemlidy neste grupo de doentes mais jovens
- Em setembro de 2022, a Gilead Sciences concluiu a aquisição da MiroBio, uma empresa de biotecnologia sediada no Reino Unido focada em restaurar o equilíbrio imunitário através de agonistas que têm como alvo os recetores imunoinibitórios. A aquisição, avaliada em aproximadamente 405 milhões de dólares, fornece à Gilead a plataforma de descoberta da MiroBio e o seu portefólio de agonistas de recetores imunoinibitórios. O principal anticorpo experimental da MiroBio, o MB272, tem como alvo as células imunes para suprimir as respostas imunes inflamatórias e está atualmente em ensaios clínicos de Fase 1. Esta aquisição reforça os esforços da Gilead no tratamento de doenças crónicas imunomediadas
- Em março de 2021, a Gilead Sciences e a Novo Nordisk expandiram a sua colaboração no tratamento da esteato-hepatite não alcoólica (NASH) iniciando um ensaio clínico de Fase 2b. O estudo investiga a segurança e a eficácia do semaglutido, um agonista do recetor GLP-1 da Novo Nordisk, combinado com o cilofexor da Gilead (um agonista do FXR) e o firsocostat (um inibidor do ACC) em doentes com cirrose devido a NASH. O ensaio irá avaliar o impacto dos tratamentos na fibrose hepática e na resolução da NASH, estando o recrutamento previsto para começar no segundo semestre de 2021.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TREATMENT TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY
4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY
4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY
4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY
4.3 EPIDEMIOLOGY
4.3.1 INCIDENCE OF ALL BY GENDER
4.3.2 TREATMENT RATE
4.3.3 TREATMENT RATE
4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
4.3.5 PATIENT TREATMENT SUCCESS RATES
4.4 MARKETED DRUG ANALYSIS
4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.5.1 PATIENT FLOW DIAGRAM
4.5.2 KEY PRICING STRATEGIES
4.5.3 KEY PATIENT ENROLLMENT STRATEGIES
5 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF LIVER DISEASES
6.1.2 RISING CONSUMPTION OF ALCOHOL
6.1.3 RISING LIVER TRANSPLANTATION RATES
6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH
6.2 RESTRAINTS
6.2.1 LIMITED AWARENESS OF LIVER DISEASES
6.2.2 REGULATORY CHALLENGES
6.3 OPPORTUNITIES
6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT
6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT
6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS
6.4 CHALLENGES
6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS
6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE
7 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 ANTIVIRAL AGENTS
7.2.1.1 VELPATASVIR/SOFOSBUVIR
7.2.1.2 TENOFOVIR
7.2.1.3 LEDIPASVIR/SOFOSBUVIR
7.2.1.4 SOFOSBUVIR
7.2.1.5 ENTECAVIR
7.2.2 ANTIFIBROTIC AGENTS
7.2.2.1 OBETICHOLIC ACID
7.2.2.2 TGF-Β INHIBITORS
7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS
7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS
7.2.2.5 OTHERS
7.2.3 ANTI-INFLAMMATORY DRUGS
7.2.3.1 CORTICOSTEROIDS
7.2.3.1.1 PREDNISONE
7.2.3.1.2 DEXAMETHASONE
7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS
7.2.3.2.1 INFLIXIMAB
7.2.3.2.2 ETANERCEPT
7.2.3.3 INTERLEUKIN (IL) INHIBITORS
7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB)
7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA)
7.2.4 IMMUNOSUPPRESSANTS
7.2.4.1 MYCOPHENOLATE MOFETIL
7.2.4.2 TACROLIMUS
7.2.4.3 CYCLOSPORINE
7.2.5 MARKETED DRUGS
7.2.5.1 VELPATASVIR/SOFOSBUVIR
7.2.5.2 TENOFOVIR
7.2.5.3 LEDIPASVIR/SOFOSBUVIR
7.2.5.4 OBETICHOLIC ACID (OCA)
7.2.5.5 SOFOSBUVIR
7.2.5.6 PIRFENIDONE
7.2.5.7 OTHERS
7.2.6 PIPELINE DRUGS
7.2.7 BRANDED DRUGS
7.2.7.1 EPCLUSA
7.2.7.2 VIREAD AND VEMLIDY
7.2.7.3 OCALIVA
7.2.7.4 HARVONI
7.2.7.5 SOVALDI
7.2.7.6 BARACLUDE
7.2.7.7 ACTOS
7.2.7.8 OTHERS
7.2.8 GENERIC DRUGS
7.2.9 ORAL
7.2.10 PARENTERAL
7.2.11 OTHERS
7.3 SURGERY/THERAPY
7.3.1 LIVER TRANSPLANTATION
7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT)
7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT)
7.3.4 SPLIT LIVER TRANSPLANTATION
7.3.5 DOMINO LIVER TRANSPLANT
7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES
7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL)
7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)
7.3.6.3 LIVER ABLATION PROCEDURES
7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA)
7.3.6.3.2 MICROWAVE ABLATION (MWA)
7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION)
7.3.7.1 SEGMENTAL RESECTION
7.3.7.2 LOBECTOMY
7.3.7.3 WEDGE RESECTION
7.3.8 CELL-BASED THERAPY
7.3.8.1 STEM CELL THERAPY
7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS)
7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS)
7.3.8.2 GENE THERAPY
7.3.8.2.1 CRISPR-BASED LIVER REGENERATION
7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS
7.3.8.2.3 SIRNA-BASED THERAPIES
7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS
7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS
7.3.8.2.4.2 EMRICASAN
7.3.8.2.4.3 PENTOXIFYLLINE
7.3.8.2.4.4 LOSARTAN
7.3.8.2.4.5 METHYL FERULIC ACID
7.3.8.2.4.6 OTHERS
7.4 OTHERS
8 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES
8.1 OVERVIEW
8.2 F2
8.3 F1
8.4 F3
8.5 F4
9 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION
9.1 OVERVIEW
9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH)
9.3 HEPATITIS B & C-INDUCED FIBROSIS
9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS
9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS
9.4 ALCOHOLIC LIVER DISEASE (ALD)
9.5 AUTOIMMUNE LIVER DISEASES
9.5.1 AUTOIMMUNE HEPATITIS (AIH)
9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC)
9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC)
9.6 GENETIC DISORDERS
9.6.1 HEMOCHROMATOSIS
9.6.2 WILSON’S DISEASE
9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY
9.7 OTHERS
10 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER
10.1 OVERVIEW
10.2 MALE
10.2.1 40-55 YEARS
10.2.2 ABOVE 55 YEARS
10.2.3 BELOW 40 YEARS
10.3 FEMALE
10.3.1 ABOVE 55 YEARS
10.3.2 40-55 YEARS
10.3.3 BELOW 40 YEARS
11 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PUBLIC HOSPITALS
11.2.2 PRIVATE HOSPITALS
11.3 SPECIALTY CLINICS
11.3.1 HEPATOLOGY CLINICS
11.3.2 GASTROENTEROLOGY CLINICS
11.4 CLINICS
11.5 AMBULATORY AND RESEARCH CENTERS
11.6 OTHERS
12 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.2.1 RETAIL SALES
12.2.1.1 HOSPITAL PHARMACY
12.2.1.2 RETAIL PHARMACY
12.2.1.3 ONLINE PHARMACY
13 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 U.A.E
13.1.4 EGYPT
13.1.5 ISRAEL
13.1.6 KUWAIT
13.1.7 QATAR
13.1.8 OMAN
13.1.9 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 GILEAD SCIENCES, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT/NEWS
16.2 ABBVIE, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 MERCK & CO, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 NOVARTIS AG
16.4.1 COMPANY SNAPSHOTS
16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 PIPELINE PRODUCT PORTFOLIO
16.4.6 RECENT DEVELOPMENT
16.5 INTERCEPT PHARMACEUTICALS, INC.
16.5.1 COMPANY SNAPSHOTS
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 PIPELINE PRODUCT PORTFOLIO
16.5.6 RECENT NEWS
16.6 ABBOTT
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 1.1.5 RECENT DEVELOPMENT
16.7 ALIGOS THERAPEUTICS
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 ALNICHE LIFE SCIENCES PVT. LTD.
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 ALENTIS THERAPEUTICS AG
16.9.1 COMPANY SNAPSHOT
16.9.2 PIPELINE PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 ADALTA LIMITED
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PIPELINE PRODUCT PORTFOLIO
16.10.4 RECENT NEWS
16.11 AKERO THERAPEUTICS, INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PIPELINE PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 BRISTOL-MYERS SQUIBB
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 CALLIDITAS THERAPEUTICS AB
16.13.1 COMPANY SNAPSHOT
16.13.2 PIPELINE PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 CUREVAC SE
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 CONATUSPHARMA
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT/NEWS
16.16 ENANTA PHARMACEUTICALS, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 ECHOSENS
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT/NEWS
16.18 F. HOFFMANN-LA ROCHE LTD
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 COMPANY SHARE ANALYSIS
16.18.4 PRODUCT PORTFOLIO
16.18.5 RECENT DEVELOPMENT
16.19 GALECTO BIOTECH
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PIPELINE PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT/NEWS
16.2 GALECTIN THERAPEUTICS, INC.
16.20.1 COMPANY SNAPSHOTS
16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS
16.20.3 PIPELINE PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
16.21 GYRE THERAPEUTICS, INC.
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENT/NEWS
16.22 GENFIT SA
16.22.1 COMPANY SNAPSHOTS
16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.22.3 PIPELINE PRODUCT PORTFOLIO
16.22.4 RECENT DEVELOPMENT
16.23 HEPION PHARMACEUTICALS
16.23.1 COMPANY SNAPSHOT
16.23.2 REVENUE ANALYSIS
16.23.3 PIPELINE PORTFOLIO
16.23.4 RECENT DEVELOPMENT
16.24 IPSEN PHARMA
16.24.1 COMPANY SNAPSHOT
16.24.2 REVENUE ANALYSIS
16.24.3 PIPELINE PRODUCT PORTFOLIO
16.24.4 RECENT NEWS/DEVELOPMENTS
16.25 LA RENON HEALTHCARE PVT. LTD.
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
16.26 MADRIGAL PHARMACEUTICALS
16.26.1 COMPANY SNAPSHOTS
16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.26.3 PRODUCT PORTFOLIO
16.26.4 RECENT DEVELOPMENT
16.27 NOVO NORDISK A/S
16.27.1 COMPANY SNAPSHOT
16.27.2 REVENUE ANALYSIS
16.27.3 PIPELINE PRODUCT PORTFOLIO
16.27.4 RECENT DEVELOPMENT
16.28 NOVOMEDIX
16.28.1 COMPANY SNAPSHOT
16.28.2 PIPELINE PRODUCT PORTFOLIO
16.28.3 RECENT DEVELOPMENT
16.29 PILANT THERAPEUTICS, INC.
16.29.1 COMPANY SNAPSHOT
16.29.2 REVENUE ANALYSIS
16.29.3 PIPELINE PRODUCT PORTFOLIO
16.29.4 RECENT NEWS
16.3 PFIZER INC.
16.30.1 COMPANY SNAPSHOT
16.30.2 REVENUE ANALYSIS
16.30.3 PIPELINE PRODUCT PORTFOLIO
16.30.4 RECENT DEVELOPMENT/NEWS
16.31 SAGIMET BIOSCIENCES
16.31.1 COMPANY SNAPSHOTS
16.31.2 REVENUE ANALYSIS
16.31.3 1.1.4 PRODUCT PORTFOLIO
16.31.4 RECENT DEVELOPMENT/NEWS
16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED
16.32.1 COMPANY SNAPSHOT
16.32.2 REVENUE ANALYSIS
16.32.3 PIPELINE PRODUCT PORTFOLIO
16.32.4 PRODUCT PORTFOLIO
16.32.5 RECENT DEVELOPMENT
16.33 TVARDI THERAPEUTICS
16.33.1 COMPANY SNAPSHOT
16.33.2 PIPELINE PRODUCT PORTFOLIO
16.33.3 RECENT DEVELOPMENT/NEWS
16.34 VERTEX PHARMACEUTICALS INCORPORATED
16.34.1 COMPANY SNAPSHOT
16.34.2 REVENUE ANALYSIS
16.34.3 PRODUCT PORTFOLIO
16.34.4 RECENT DEVELOPMENT
16.35 VIKING THERAPEUTICS
16.35.1 COMPANY SNAPSHOT
16.35.2 REVENUE ANALYSIS
16.35.3 PIPELINE PRODUCT PORTFOLIO
16.35.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Lista de Tabela
TABLE 1 MIDDLE EAST AND AFRICA INCIDENCE OF CIRRHOSIS BY GENDER (2019)
TABLE 2 TREATMENT ADHERENCE LEVELS IN LIVER DISEASE PATIENTS
TABLE 3 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 7 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 9 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 10 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 12 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 13 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 16 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 17 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 19 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 20 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 22 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 23 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 24 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 26 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 27 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA F2 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA F1 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA F3 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA F4 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA ALCOHOLIC LIVER DISEASE (ALD) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA AMBULATORY AND RESEARCH CENTERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA DIRECT TENDER IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 78 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 80 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 81 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 83 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 84 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 86 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 88 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 89 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 91 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 92 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 94 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 95 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 97 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 98 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 99 MIDDLE EAST AND AFRICA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 MIDDLE EAST AND AFRICA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 103 MIDDLE EAST AND AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 MIDDLE EAST AND AFRICA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 MIDDLE EAST AND AFRICA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 MIDDLE EAST AND AFRICA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 MIDDLE EAST AND AFRICA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 MIDDLE EAST AND AFRICA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 MIDDLE EAST AND AFRICA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 MIDDLE EAST AND AFRICA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 MIDDLE EAST AND AFRICA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 113 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 114 MIDDLE EAST AND AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 MIDDLE EAST AND AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 118 MIDDLE EAST AND AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 MIDDLE EAST AND AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 121 MIDDLE EAST AND AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 124 MIDDLE EAST AND AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 128 SOUTH AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 SOUTH AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 130 SOUTH AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 131 SOUTH AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 SOUTH AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 133 SOUTH AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 134 SOUTH AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 SOUTH AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 136 SOUTH AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 SOUTH AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 138 SOUTH AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 139 SOUTH AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 SOUTH AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 141 SOUTH AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 142 SOUTH AFRICA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 SOUTH AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 144 SOUTH AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 145 SOUTH AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 SOUTH AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 147 SOUTH AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 148 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 149 SOUTH AFRICA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 SOUTH AFRICA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 153 SOUTH AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 SOUTH AFRICA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 SOUTH AFRICA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 SOUTH AFRICA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 SOUTH AFRICA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 SOUTH AFRICA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 SOUTH AFRICA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 SOUTH AFRICA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 SOUTH AFRICA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 163 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 164 SOUTH AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 SOUTH AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 SOUTH AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 168 SOUTH AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 SOUTH AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 171 SOUTH AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 SOUTH AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 174 SOUTH AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 178 SAUDI ARABIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 SAUDI ARABIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 180 SAUDI ARABIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 181 SAUDI ARABIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 SAUDI ARABIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 183 SAUDI ARABIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 184 SAUDI ARABIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 SAUDI ARABIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 186 SAUDI ARABIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 187 SAUDI ARABIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 188 SAUDI ARABIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 189 SAUDI ARABIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 SAUDI ARABIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 191 SAUDI ARABIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 192 SAUDI ARABIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 SAUDI ARABIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 194 SAUDI ARABIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 195 SAUDI ARABIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 SAUDI ARABIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 197 SAUDI ARABIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 198 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 199 SAUDI ARABIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 SAUDI ARABIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 203 SAUDI ARABIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 SAUDI ARABIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 SAUDI ARABIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 SAUDI ARABIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 SAUDI ARABIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 SAUDI ARABIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 SAUDI ARABIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 SAUDI ARABIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 SAUDI ARABIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 213 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 214 SAUDI ARABIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 SAUDI ARABIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 SAUDI ARABIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 218 SAUDI ARABIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 SAUDI ARABIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 221 SAUDI ARABIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 SAUDI ARABIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 224 SAUDI ARABIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 228 U.A.E ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 U.A.E ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 230 U.A.E ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 231 U.A.E ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 U.A.E ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 233 U.A.E ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 234 U.A.E ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 235 U.A.E ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 236 U.A.E CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 U.A.E CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 238 U.A.E CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 239 U.A.E TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 U.A.E TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 241 U.A.E TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 242 U.A.E INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 U.A.E INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 244 U.A.E INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 245 U.A.E IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 U.A.E IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 247 U.A.E IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 248 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 249 U.A.E MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 U.A.E BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 253 U.A.E SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 U.A.E LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 U.A.E ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 U.A.E LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 U.A.E PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 U.A.E CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 U.A.E STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 U.A.E GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 U.A.E HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 263 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 264 U.A.E HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 U.A.E AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 U.A.E GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 268 U.A.E MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 U.A.E FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 271 U.A.E HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 U.A.E SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 274 U.A.E RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 278 EGYPT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 EGYPT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 280 EGYPT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 281 EGYPT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 EGYPT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 283 EGYPT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 284 EGYPT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 EGYPT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 286 EGYPT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 EGYPT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 288 EGYPT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 289 EGYPT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 EGYPT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 291 EGYPT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 292 EGYPT INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 EGYPT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 294 EGYPT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 295 EGYPT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 EGYPT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 297 EGYPT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 298 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 299 EGYPT MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 EGYPT BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 303 EGYPT SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 EGYPT LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 EGYPT ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 EGYPT LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 EGYPT PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 308 EGYPT CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 EGYPT STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 EGYPT GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 EGYPT HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 312 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 313 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 314 EGYPT HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 315 EGYPT AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 316 EGYPT GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 317 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 318 EGYPT MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 EGYPT FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 321 EGYPT HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 322 EGYPT SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 324 EGYPT RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 328 ISRAEL ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 ISRAEL ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 330 ISRAEL ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 331 ISRAEL ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 ISRAEL ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 333 ISRAEL ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 334 ISRAEL ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 ISRAEL ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 336 ISRAEL CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 337 ISRAEL CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 338 ISRAEL CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 339 ISRAEL TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 340 ISRAEL TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 341 ISRAEL TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 342 ISRAEL INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 343 ISRAEL INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 344 ISRAEL INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 345 ISRAEL IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 ISRAEL IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 347 ISRAEL IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 348 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 349 ISRAEL MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 ISRAEL BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 353 ISRAEL SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 ISRAEL LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 ISRAEL ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 ISRAEL LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 ISRAEL PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 358 ISRAEL CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 359 ISRAEL STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 360 ISRAEL GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 ISRAEL HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 363 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 364 ISRAEL HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 ISRAEL AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 366 ISRAEL GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 367 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 368 ISRAEL MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 ISRAEL FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 371 ISRAEL HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 ISRAEL SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 374 ISRAEL RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 377 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 378 KUWAIT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 KUWAIT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 380 KUWAIT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 381 KUWAIT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 KUWAIT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 383 KUWAIT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 384 KUWAIT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 KUWAIT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 386 KUWAIT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 KUWAIT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 388 KUWAIT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 389 KUWAIT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 KUWAIT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 391 KUWAIT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 392 KUWAIT INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 KUWAIT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 394 KUWAIT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 395 KUWAIT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 KUWAIT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 397 KUWAIT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 398 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 399 KUWAIT MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 400 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 KUWAIT BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 403 KUWAIT SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 KUWAIT LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 405 KUWAIT ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 406 KUWAIT LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 KUWAIT PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 KUWAIT CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 KUWAIT STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 KUWAIT GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 KUWAIT HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 413 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 414 KUWAIT HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 KUWAIT AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 KUWAIT GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 418 KUWAIT MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 KUWAIT FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 420 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 421 KUWAIT HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 KUWAIT SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 424 KUWAIT RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 QATAR LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 427 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 428 QATAR ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 429 QATAR ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 430 QATAR ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 431 QATAR ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 432 QATAR ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 433 QATAR ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 434 QATAR ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 QATAR ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 436 QATAR CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 QATAR CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 438 QATAR CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 439 QATAR TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 QATAR TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 441 QATAR TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 442 QATAR INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 QATAR INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 444 QATAR INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 445 QATAR IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 446 QATAR IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 447 QATAR IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 448 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 449 QATAR MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 QATAR BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 453 QATAR SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 454 QATAR LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 455 QATAR ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 QATAR LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 QATAR PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 QATAR CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 QATAR STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 QATAR GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 461 QATAR HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 462 QATAR LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 463 QATAR LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 464 QATAR HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 QATAR AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 QATAR GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 QATAR LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 468 QATAR MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 469 QATAR FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 470 QATAR LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 471 QATAR HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 472 QATAR SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 473 QATAR LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 474 QATAR RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 475 OMAN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 478 OMAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 OMAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 480 OMAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 481 OMAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 OMAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 483 OMAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 484 OMAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 485 OMAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 486 OMAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 OMAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 488 OMAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 489 OMAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 OMAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 491 OMAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 492 OMAN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 493 OMAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 494 OMAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 495 OMAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 496 OMAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 497 OMAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 498 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 499 OMAN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 500 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 501 OMAN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 503 OMAN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 OMAN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 505 OMAN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 506 OMAN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 507 OMAN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 OMAN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 OMAN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 OMAN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 OMAN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 512 OMAN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 513 OMAN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 514 OMAN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 OMAN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 516 OMAN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 517 OMAN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 518 OMAN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 519 OMAN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 520 OMAN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 521 OMAN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 522 OMAN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 523 OMAN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 524 OMAN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 REST OF MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
Lista de Figura
FIGURE 1 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LIVER DISEASES IS EXPECTED TO DRIVE THE GROWTH OF MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET FROM 2025 TO 2032
FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET IN 2025-2032
FIGURE 13 TWO SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE
FIGURE 14 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 15 STRATEGIC DECISIONS
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET
FIGURE 17 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 18 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 19 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 20 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2024
FIGURE 22 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2025-2032 (USD THOUSAND)
FIGURE 23 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, CAGR (2025-2032)
FIGURE 24 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2024
FIGURE 26 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2025-2032 (USD THOUSAND)
FIGURE 27 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, CAGR (2025-2032)
FIGURE 28 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2024
FIGURE 30 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)
FIGURE 31 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, CAGR (2025-2032)
FIGURE 32 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2024
FIGURE 34 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 35 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 36 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2024
FIGURE 38 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 39 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 40 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 42 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: COMPANY SHARE 2024 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
